Corcept Therapeutics (CORT) Net Margin (2012 - 2026)

Corcept Therapeutics has reported Net Margin for 15 years, with the latest figure at 16.45% in Q2 2026.

• Quarterly Net Margin fell 135.0% year-over-year to 16.45% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 6.52% (down 1191.0% YoY) and the FY2025 annual result came in at 12.89%, down 781.0% from the prior year.
• Net Margin advanced to 16.45% in Q2 2026 per CORT's latest filing, from 18.92% in the prior quarter.
• Over five years, Net Margin peaked at 33.96% in Q3 2022 and troughed at 18.92% in Q1 2026.
• A 5-year average of 17.73% and a median of 18.27% in 2025 frame the typical range for Net Margin.
• The sharpest annual moves came in 2023 and 2026: Net Margin surged 696 bps in 2023, then sank 3183 bps in 2026.
• Over 5 years, Net Margin stood at 16.04% in 2022, then surged by 43 bps to 23.0% in 2023, then slipped by 27 bps to 16.71% in 2024, then slipped by 29 bps to 11.83% in 2025, then soared by 39 bps to 16.45% in 2026.
• According to Business Quant data, Net Margin over the past three periods registered 16.45%, 18.92%, and 11.83% for Q2 2026, Q1 2026, and Q4 2025 respectively.